论文部分内容阅读
在世界首个基因治疗药物“今又生”获得新药证书7年之后,它的命运又增变数。两个围绕着“今又生”、其生产企业赛百诺以及赛百诺的控股公司奔达药业的官司可以说是主要肇因。战场之一在美国。2010年初,奔达的第二大股东和最大的债权人美国Pope资产管理公司向特拉华州高等法院起诉,以股价长期徘徊在几美分的奔达资不抵债为由要求对其进行清算和接管。
Seven years after the world’s first gene therapy drug, “Now and then,” has obtained a new drug certificate, its fate has changed again. The two lawsuits surrounding Bennett, the maker of Seabunet and its controlling company, Bennett, are the main cause. One of the battlefields in the United States. In early 2010, Pope Asset Management, the second largest shareholder and largest creditor of BOND, filed a lawsuit in the Delaware High Court demanding that its liquidation should be settled on the grounds that Bendeli’s shares, whose share price has been hovering for a long time, take over.